Taking this specific combination of green tea and grape-derived supplements for 12 weeks helps the muscle cells in overweight and obese people make more energy, like upgrading their internal batteries.
Scientific Claim
Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol increases mitochondrial oxidative capacity in skeletal muscle of overweight and obese adults, as measured in permeabilized muscle fibers, suggesting enhanced cellular energy production potential.
Original Statement
“EGCG+RES supplementation significantly increased oxidative capacity in permeabilized muscle fibers (P-time × treatment < 0.05, P-EGCG+RES < 0.05).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The RCT design supports causal inference, but abstract-only access limits verification of methodology details like muscle biopsy quality or confounder control. 'Increases' is appropriate but should be tempered with probability language given limited data.
More Accurate Statement
“Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol likely increases mitochondrial oxidative capacity in skeletal muscle of overweight and obese adults, as measured in permeabilized muscle fibers.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether EGCG+RES consistently increases mitochondrial oxidative capacity across diverse obese populations and dosages, and whether effects are durable or dose-dependent.
Whether EGCG+RES consistently increases mitochondrial oxidative capacity across diverse obese populations and dosages, and whether effects are durable or dose-dependent.
What This Would Prove
Whether EGCG+RES consistently increases mitochondrial oxidative capacity across diverse obese populations and dosages, and whether effects are durable or dose-dependent.
Ideal Study Design
A systematic review and meta-analysis of at least 5 high-quality RCTs (n≥100 per trial) in overweight/obese adults (BMI 27–40, aged 30–65) comparing EGCG+RES (282+80 mg/d) vs placebo for ≥12 weeks, with primary outcome of skeletal muscle mitochondrial oxidative capacity measured via high-resolution respirometry in permeabilized fibers.
Limitation: Cannot establish individual-level causality or identify subpopulations most likely to respond.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of EGCG+RES on mitochondrial capacity in a larger, more diverse obese population with standardized muscle biopsy protocols.
Causal effect of EGCG+RES on mitochondrial capacity in a larger, more diverse obese population with standardized muscle biopsy protocols.
What This Would Prove
Causal effect of EGCG+RES on mitochondrial capacity in a larger, more diverse obese population with standardized muscle biopsy protocols.
Ideal Study Design
A double-blind, placebo-controlled RCT with 150 overweight/obese adults (BMI 28–35, aged 35–60), randomized to EGCG+RES (282+80 mg/d) or placebo for 12 weeks, with primary endpoint: mitochondrial oxidative capacity in vastus lateralis muscle fibers measured by high-resolution respirometry, controlled for diet, physical activity, and insulin sensitivity.
Limitation: Cannot determine long-term effects beyond 12 weeks or clinical relevance to metabolic disease.
Prospective Cohort StudyLevel 2bWhether increased mitochondrial capacity from EGCG+RES supplementation predicts long-term improvements in metabolic health outcomes like type 2 diabetes incidence.
Whether increased mitochondrial capacity from EGCG+RES supplementation predicts long-term improvements in metabolic health outcomes like type 2 diabetes incidence.
What This Would Prove
Whether increased mitochondrial capacity from EGCG+RES supplementation predicts long-term improvements in metabolic health outcomes like type 2 diabetes incidence.
Ideal Study Design
A 5-year prospective cohort of 500 obese adults (BMI ≥28) who either take or do not take EGCG+RES (282+80 mg/d), with annual measurements of mitochondrial capacity, insulin sensitivity, and incident type 2 diabetes, adjusting for lifestyle and medication use.
Limitation: Cannot prove causation due to potential confounding by adherence and lifestyle factors.
Animal Model StudyLevel 4Mechanistic pathways by which EGCG+RES enhances mitochondrial biogenesis or function in adipose or muscle tissue.
Mechanistic pathways by which EGCG+RES enhances mitochondrial biogenesis or function in adipose or muscle tissue.
What This Would Prove
Mechanistic pathways by which EGCG+RES enhances mitochondrial biogenesis or function in adipose or muscle tissue.
Ideal Study Design
A study in diet-induced obese mice (C57BL/6, 12 weeks high-fat diet) treated with EGCG+RES (equivalent human dose) for 12 weeks, measuring mitochondrial DNA copy number, PGC-1α expression, and electron transport chain protein levels in skeletal muscle via Western blot and qPCR.
Limitation: Cannot confirm translation to human physiology or clinical outcomes.
Evidence from Studies
Supporting (1)
This study gave overweight people the exact same supplements for 12 weeks and found their muscle cells got better at making energy — just like the claim said.